Tag "biotechnology"

Biotech ETF (XBI) On The Brink Of A Breakout

The volatility in the biotech space over the last two years has been quite a sight to behold. I’m not strictly speaking of volatility in terms of downside either. There has been money to be made on both sides of the market for those that have been nimble in their…

Biotechnology Sector Testing Bull Market Trendline

When this market cycle finally comes to an end, among the sectors that will be remembered as one of its key drivers is biotechnology. With a gaudy 750% gain since its 2009 lows, the Biotech run had been so hot, it attracted “bubble” talk in its descriptions, including by us back…

What’s Next For Biotech Stocks? Watch This Trend Line

There has been a lot of buzz surrounding the recent weakness in the Biotech stocks as traders try to digest the recent bouts of selling pressure. After overheating back in March, the Biotech sector sold off hard before staging a rally into April. But that rally failed to reach new highs…

Why The Biotech Sector ETF (IBB) Is “Distributing” Pain

A few days ago I tweeted that the iShares Nasdaq Biotechnology ETF (IBB) looked to have entered a period of clear “distribution”, meaning that strength begets selling rather than the opposite. It is not shocking since in DeMark terms the Biotech Sector ETF is printing ominous “exhaustion” signals on daily,…

The Amazing Run In Biotech Stocks

Biotech stocks have been on fire in 2015. In the Biotech & Pharmaceuticals sector of the Russell 2000 Growth Index, there are over sixty stocks up by more than 30% this year. More than thirty stocks are up greater than 50% while six have more than doubled. The iShares Biotechnology…

Biotech Takes Ill In Worst Selloff Since April

In the category of market defeat snatched from the jaws of victory, the super-heated Biotech industry is showing early signs of relapsing into the technically challenged behavior it briefly displayed back in the Spring.  One of the “Charts to Watch During the Summer Doldrums“, the iShares NASDAQ Biotechnology ETF (IBB)…

Biotech IPOs: New Market Paradigm or Nearing a Cliff?

Within the last 6 months, 22 Biotech IPOs have occurred in the US. Though that may seem modest in a market populated by thousands of stocks, the figure represents a deluge of companies dashing for cash inside the violent IPO current sweeping through the broader market. “The Biotech window is…

Biotech Bubble? The Nervous Speculator’s Field Guide

By definition, any trend that becomes so axiomatic for the market that not participating seems obscene has entered its latter days. Three weeks ago we checked in on the largest stocks (by market cap) in the soaring Biotechnology industry, concluding that apprehensive observations voiced about an expanding bubble there may…

BioShock: Why Biotech Bubble Fears Are On Solid Ground

What’s left to be said about the quickening madness that has every appearance of spooling into a classic mania in Biotech stocks? Sean McLaughlin summed up the current environment well when he wryly observed yesterday on the Stocktwits blog that “We might never know why, but make no mistake, risk…

Amgen Ready for a Technical Bounce

After a strong 3 month move from February to May that delivered a pop through its long term upper wedgeline, Amgen Inc. (AMGN) has been pretty weak, failing to follow through on its breakout.  Now it’s do or die time, as the charts indicate a slight backtest violation of that very…